The persistent epithelial defect management market is projected to grow from USD 11.8 billion in 2025 to USD 56.4 billion by 2035, at a CAGR of 16.9%. Epithelial/Limbal will dominate with a 47.2% market share, while hospitals/clinical laboratories will lead the end user segment with a 53.6% share.